LRA-Funded Findings Suggest Way to Help Reverse Lupus Nephritis
June 15, 2020 A recently published study explored how an unconventional treatment method undergoing clinical trials in cancer patients could help lessen the severity of lupus nephritis (inflammation of the kidneys), a common and serious condition in people with lupus. Funded by the Lupus Research Alliance, this study, published in the journal, Science Translational Medicine, […]
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2019
Pharmaceutical and Biotech Support of the Lupus Research Alliance – 2019 The Lupus Research Alliance’s vision is a world free of lupus – by finding ways to prevent, treat and one day cure this disease. We work diligently to forge appropriate relationships with members of the pharmaceutical and biotech industries that share our vision and […]
Looking at Iron as a Trigger for Lupus Nephritis
As the provider of life-giving oxygen to organ systems through its role in red blood cell production — the health benefits of iron are tremendous. This essential element is vital for proper growth throughout the body and for robust cellular health. But what happens when a good thing goes bad, and iron makes cells die? […]
LRA-funded Research Backs New Lupus Nephritis Clinical Trial
February 28, 2019 The biotechnology company Equillium Inc. just announced plans for a Phase 1 study to test the investigational monoclonal antibody EQ001 as a potential treatment for lupus nephritis (LN) that has not responded to existing treatment. The basis for this study is in part due to work conducted by Dr. Chandra Mohan that […]
LRA Shares Excitement For What’s Ahead in Lupus Nephritis
January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […]
LRA Uncovering What Causes Lupus Nephritis to Improve Treatment
January 16, 2020 The Lupus Research Alliance has invested millions in research to get us to the point we’re at with potential new treatments for LN. We are proud to share what just ten of our funded scientists are doing right now to discover what causes lupus nephritis and how it can be better diagnosed, […]
Protein Osteopontin Indicator of Lupus Nephritis, Shows Clinical Trial
February 1, 2019 Raised levels of a protein osteopontin were shown to indicate lupus nephritis and higher disease activity, in a new study conducted at 33 centers by top lupus researchers worldwide. Published in The Journal of Rheumatology, the study looked at results from 344 lupus patients. At the beginning of the study (baseline), patients […]
FDA Expedites Existing Drug Gazyva for Lupus Nephritis
September 18, 2019 The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva®) for adults with lupus nephritis – the most common complication of lupus. The FDA’s designation aims to speed up the development and review of drugs intended to treat a serious condition […]
LRA Pleased to Share News of Lupus Nephritis Clinical Trial Launch
October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […]
Less Risk and Greater Efficacy in Pediatric Lupus Nephritis Treatment
November 3, 2020 There is no doubt about it. The research into the mechanisms of pediatric lupus nephritis conducted by Elena Hsieh, MD, at the University of Colorado Anschutz Medical Campus, is driven by her genuine concern for the wellbeing of children—and a lifelong passion for science. With her new grant from the Lupus Research […]